Analysts Turn Bullish on Biohaven, Caris, and Veracyte
Canaccord says Biohaven is undervalued and could rise on epilepsy trial results. Jefferies likes Caris Life Sciences and Veracyte, citing strong growth in cancer diagnostics and solid finances.
NOTRELOAD AI
Roblox Launches Roblox Kids and Roblox Select Accounts to Boost Child Safety
Roblox adds safer kids accounts with age checks, limited chat, and stricter rules to protect young players from online risks.
TD Securities Sees Strong 2026 Growth for Tempus AI
TD Cowen upgraded Tempus AI to Buy, $65 target, citing strong growth in AI pharma tools despite recent stock drop.
Jhunjhunwala-Backed IKS in Advanced Talks to Buy Nasdaq’s TruBridge for $600M
IKS nearing $600M buy of TruBridge to boost US healthcare billing/RCM, expand AI-driven services and market share.
Pancreatic Cancer Breakthrough: New Daily Pill Nearly Doubles Survival in Major Trial
New drug daraxonrasib from Revolution Medicines doubled survival in pancreatic cancer (13.2 vs 6.7 months) and cut death risk by 60% in Phase 3.
Allogene’s Off-the-Shelf CAR-T Wipes Out Hidden Cancer Cells in 58% of High-Risk Lymphoma Patients – Early Trial Success
Allogene’s CAR-T cema-cel showed strong early results in lymphoma, removing hidden cancer better than watchful waiting with good safety.